Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

被引：0
|
作者：
Sanne ten Hoorn
Dirkje W. Sommeijer
Faye Elliott
David Fisher
Tim R. de Back
Anne Trinh
Lianne Koens
Tim Maughan
Jenny Seligmann
Matthew T. Seymour
Phil Quirke
Richard Adams
Susan D. Richman
Cornelis J. A. Punt
Louis Vermeulen
机构：
[1] Amsterdam UMC,Department of Medical Oncology, Amsterdam UMC
[2] University of Amsterdam,Leeds Institute of Medical Research at St James’s
[3] LEXOR,MRC Clinical Trials Unit
[4] Center for Experimental and Molecular Medicine,Department of Medical Oncology
[5] Cancer Center Amsterdam,Department of Medicine
[6] Oncode Institute,Department of Pathology, Amsterdam UMC
[7] Amsterdam UMC,Department of Oncology
[8] University of Amsterdam,Department of Epidemiology, Julius Center for Health Sciences and Primary Care
[9] Flevohospital,undefined
[10] Department of Internal Medicine,undefined
[11] University of Leeds,undefined
[12] St James’s University Hospital,undefined
[13] University College London,undefined
[14] Dana-Farber Cancer Institute,undefined
[15] Harvard Medical School,undefined
[16] University of Amsterdam,undefined
[17] University of Oxford,undefined
[18] Centre for Trials Research Cardiff University and Velindre Hospital,undefined
[19] University Medical Center,undefined
[20] Utrecht University,undefined
来源：
British Journal of Cancer | 2021年 / 125卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1080 / 1088
页数：8
相关论文
共 50 条
  • [41] Association of bevacizumab-free interval with efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer.
    Komori, Azusa
    Taniguchi, Hiroya
    Narita, Yukiya
    Uegaki, Shiori
    Nitta, Sohhei
    Yamaguchi, Kazuhisa
    Nomura, Motoo
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
    Kasi, Pashtoon Murtaza
    Afable, Manuel Geroy
    Herting, Cameron
    Lukanowski, Mariusz
    Jin, Zhaohui
    [J]. ONCOLOGIST, 2023, : 1034 - 1048
  • [43] Anti-EGFR monoclonal antibody treatment in colorectal cancer
    [J]. Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 (6): : 249 - 250
  • [44] Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer
    Vecchione, Loredana
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2014, 10 (03) : 263 - 271
  • [45] Unexpected insights for anti-EGFR cancer therapy
    Depeille, Philippe
    Warren, Robert S.
    Roose, Jeroen P.
    [J]. ONCOTARGET, 2015, 6 (22) : 18746 - 18747
  • [46] Integrating anti-EGFR therapies in metastatic colorectal cancer
    Haraldsdottir, Sigurdis
    Bekaii-Saab, Tanios
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (03) : 285 - 298
  • [47] PREDICTIVE MOLECULAR BIOMARKERS IN COLORECTAL CANCER: IS KRAS AND BRAF WILD TYPE STATUS REQUIRED FOR ANTI-EGFR THERAPY?
    Marchoudi, N.
    Joutei, H. Amrani Hassani
    Jouali, F.
    Fekkak, J.
    Rhaissi, H.
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 6048 - 6048
  • [48] Epidermal growth factor receptor (EGFR) expression in colorectal cancer and clinical outcome of anti-EGFR therapy
    Wei, EX
    Abreo, F
    Nordberg, ML
    [J]. MODERN PATHOLOGY, 2005, 18 : 122A - 122A
  • [49] Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis
    Wu, Qian
    Wang, Huan
    Zhang, Suqin
    Zeng, Yifei
    Yang, Wei
    Pan, Wenjun
    Hong, Guodai
    Gao, Wenbin
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [50] RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer
    Rich, T. A.
    Clifton, K.
    Grothey, A.
    Hendifar, A.
    Henry, D. H.
    Kagawa, Y.
    Nakamura, Y.
    Okamoto, W.
    Tan, B. R.
    Sherrill, G.
    Yoshino, T.
    Raymond, V. M.
    Shiotsu, Y.
    Lanman, R. B.
    Morris, V.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 162 - 162
12345